MAO-A inhibitors(Monoamine oxidase A inhibitors), MTNR1A modulators(Melatonin receptor 1A modulators), σ1 receptor modulators(Sigma opioid receptor modulators)

Therapeutic Areas

Other Diseases

Active Indication

Anxiety Disorders

Inactive Indication-

Originator Organization

Pharmstandard PJSC

Active Organization

Pharmstandard PJSC

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date-

Regulation-

Structure

Molecular FormulaC15H21N3O2S

InChIKeyWWNUCVSRRUDYPP-UHFFFAOYSA-N

CAS Registry173352-21-1

100 Clinical Results associated with Fabomotizole

100 Translational Medicine associated with Fabomotizole

100 Patents (Medical) associated with Fabomotizole

Literatures (Medical) associated with Fabomotizole

01 Jul 2024·Bulletin of Experimental Biology and Medicine

Body Surface Potential Mapping during Atrial Depolarization in Rats with Post-Infarction Chronic Heart Failure against the Background of Fabomotizole Therapy

Article

Author: Ivonin, A G ; Kryzhanovskii, S A ; Tsorin, I B ; Roshchevskaya, I M ; Smirnova, S L ; Barchukov, V V

Cardiac remodeling in rats with post-infarction chronic heart failure caused by anterior transmural myocardial infarction leads to an atypical location of areas of positive and negative cardioelectric potentials on the body surface before the onset of the P_II-wave on the ECG in the limb leads, which is a sign of increased heterogeneity of atrial depolarization associated with the appearance of additional excitation focus in the left atrium. A course of therapy with fabomotizole leads to a decrease in the heterogeneity of atrial depolarization at the initial stages of the formation of the cardioelectric field of the atria on the body surface before the onset of the P_II-wave, thereby producing an antiarrhythmic effect.

01 Dec 2023·Bulletin of Experimental Biology and Medicine

The Effect of Original Russian Neurotropic Drugs on Organic Anion Transporting Polypeptides OATP1B1 and OATP1B3

Article

Author: Konyakhin, E A ; Ganina, S O ; Yakusheva, E N ; Mylnikov, P Yu ; Abalenikhina, Yu V ; Shchulkin, A V ; Petrov, A V ; Erokhina, P D

In experiments on HepG2 cells, we studied the effect of the original domestic neurotropic drugs omberacetam, fabomotizole, and ethylmethylhydroxypyridine succinate (EMHPS) (1-500 μM) on the activity and content of organic anion transporting polypeptides OATP1B1 and OATP1B3. It was shown that omberacetam (500 μM) increased the content of OATP1B1 and OATP1B3, fabomotizole did not affect the level of both transporters, and EMHPS (500 μM) increased the content of OATP1B1 compared to the control and did not affect the level of OATP1B3. The tested substances also reduced the OATP1B1/OATP1B3 ratio, as evidenced by a decrease in the penetration of atorvastatin, a substrate of the transporters, into HepG2 cells in the presence of omberacetam (100-500 μM), fabomotizole (500 μM), and EMHPS (10-500 μM). Evaluation of clinical significance of the obtained results, according to the FDA approach based on the calculation of the C_max/IC₅₀ ratio, showed that the effect of the tested substances on OATP1B1/OATP1B3 is clinically insignificant.

01 May 2021·Bulletin of Experimental Biology and MedicineQ4 · MEDICINE

On the Mechanism of Cardioprotective Effect of Fabomotizole in Alcoholic Cardiomyopathy

Q4 · MEDICINE

Article

Author: Stolyaruk, V N ; Vititnova, M B ; Efimova, A O ; Kozhevnikova, L M ; Kryzhanovskii, S A ; Tsorin, I B

The molecular mechanisms underlying the cardioprotective effect of fabomotizole were studied using the translational rat model of alcoholic cardiomyopathy developed by us. It was shown that intraperitoneal administration of fabomotizole (15 mg/kg) for 28 days to animals with alcoholic cardiomyopathy contributes to normalization of the expression of mRNA of genes of regulatory proteins СаМ (p=0.00001), Ерас1 (p=0.021), and Ерас2 (p=0.018) and receptors RyR2 (p=0.0031) and IP3R2 (p=0.006) in the myocardium of the myocardium of the left ventricle that is enhanced in control animals (p<0.05). These changes were accompanied by echocardiographically documented decrease in the degree of left ventricle remodeling and improvement of its inotropic function.

100 Deals associated with Fabomotizole

External Link

KEGG	Wiki	ATC	Drug Bank
-	Fabomotizole	N05BX04	DB13623

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Anxiety Disorders	RU	Pharmstandard PJSC	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis